- Home
- PYN vs CALC Comparison
PYN vs CALC Comparison
Compare PYN & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYN
- CALC
- Stock Information
- Founded
- PYN 2002
- CALC 2011
- Country
- PYN United States
- CALC United States
- Employees
- PYN N/A
- CALC N/A
- Industry
- PYN Investment Managers
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- PYN Finance
- CALC Health Care
- Exchange
- PYN Nasdaq
- CALC Nasdaq
- Market Cap
- PYN N/A
- CALC 20.9M
- IPO Year
- PYN N/A
- CALC N/A
- Fundamental
- Price
- PYN $5.47
- CALC $2.07
- Analyst Decision
- PYN
- CALC Strong Buy
- Analyst Count
- PYN 0
- CALC 3
- Target Price
- PYN N/A
- CALC $16.33
- AVG Volume (30 Days)
- PYN 19.9K
- CALC 28.2K
- Earning Date
- PYN 01-01-0001
- CALC 05-20-2025
- Dividend Yield
- PYN 5.07%
- CALC N/A
- EPS Growth
- PYN N/A
- CALC N/A
- EPS
- PYN N/A
- CALC N/A
- Revenue
- PYN N/A
- CALC N/A
- Revenue This Year
- PYN N/A
- CALC N/A
- Revenue Next Year
- PYN N/A
- CALC N/A
- P/E Ratio
- PYN N/A
- CALC N/A
- Revenue Growth
- PYN N/A
- CALC N/A
- 52 Week Low
- PYN $4.84
- CALC $1.43
- 52 Week High
- PYN $6.60
- CALC $6.02
- Technical
- Relative Strength Index (RSI)
- PYN 54.57
- CALC 63.05
- Support Level
- PYN $5.34
- CALC $1.52
- Resistance Level
- PYN $5.48
- CALC $2.15
- Average True Range (ATR)
- PYN 0.07
- CALC 0.13
- MACD
- PYN 0.03
- CALC 0.08
- Stochastic Oscillator
- PYN 90.62
- CALC 73.61
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.